Meeting
2021 ASCO Annual Meeting
Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.
Authors
Ryan C Miller
Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA
Ryan C Miller , Andrew Jehyun Song , Ayesha Ali , Voichita C Bar-Ad , Nina Leyson Martinez , Jon Glass , Iyad Alnahhas , David W. Andrews , Kevin Judy , James J Evans , Christopher Farrell , Maria Werner-Wasik , Inna Chervoneva , Michele Ly , Joshua David Palmer , Haisong Liu , Wenyin Shi
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Central Nervous System Tumors
Track
Central Nervous System Tumors
Sub Track
Primary CNS Tumors–Glioma
Clinical Trial Registration Number
NCT03477110
Citation
J Clin Oncol 39, 2021 (suppl 15; abstr 2056)
DOI
10.1200/JCO.2021.39.15_suppl.2056
Abstract #
2056
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
Phase I study of drug-resistant immunotherapy (DRI) with gene-modified autologous γδ T cells in patients with newly diagnosed glioblastoma multiforme (GBM) receiving maintenance temozolomide (TMZ).
First Author: Louis B. Nabors
Poster
2020 ASCO Virtual Scientific Program
Phase III TRIDENT trial: Radiation and temozolomide +/- tumor treating fields in newly diagnosed glioblastoma.
First Author: Wenyin Shi
Poster
2017 ASCO Annual Meeting
Phase II trial of bevacizumab and temozolomide for upfront treatment of elderly patients with newly diagnosed glioblastoma.
First Author: Phioanh Leia Nghiemphu
Poster
2014 ASCO Annual Meeting
Phase II trial of vorinostat (VOR) combined with temozolomide (TMZ) and radiation therapy (RT) for newly diagnosed glioblastoma (GBM) (Alliance N0874/ABTC-0902).
First Author: Evanthia Galanis